Frontlight ResearchEarly access
TerminatedPhase 2/3
Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
Key facts
- Who runs it
- LeonaBio
- Where
- Rochester, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 2/3
- People taking part
- 423 people enrolled
- Started
- 30 Jun 2021
- Ended
- 23 Oct 2024
- Type of study
- Interventional
- Treatments tested
- ATH-1017
- Record updated
- 1 April 2025
- Why it stopped
- ATH-1017-AD-0203 was terminated after the Ph2/3 parent trial (LIFT-AD; NCT04488419) did not meet its primary endpoint, the GST score.
Who can take part
- Age
- 55 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Subject has completed the Week 26 visit of either of the two blinded parent studies (ATH-1017-AD-0201 or ATH-1017-AD-0202)
- Reliable and capable support person/caregiver who is willing to accept responsibility for supervising the daily treatment or, if required, administering study drug
- Subject capable of giving signed informed consent, or by a legally acceptable representative
- Subjects must be in generally good health
- Male subjects and their partners must agree to continue to use a double-barrier method of contraception during the study, including the follow-up period, unless the partner is not of childbearing potential
Who cannot take part
- New diagnosis of severe major depressive disorder even without psychotic features
- Newly-diagnosed malignant tumor, except for the following conditions that are stable in the judgement of the investigator:; Adequately treated squamous and basal cell carcinoma, or squamous and basal cell carcinoma in situ; Prostate carcinoma in situ
- Subject has experienced a serious adverse event during the parent study, which could present an increased safety risk during the open label extension
- Any subject with formalized delusions or hallucinations
- Significant suicide risk
Where in United States
- University of Rochester-AD-CARE ProgramRochester, United States
About the trial
What the trial wants to find out
The objective of this study is to determine the safety and tolerability of fosgonimeton (ATH-1017) in subjects with mild to moderate Alzheimer's disease who completed the 26-week randomized treatment in Study ATH-1017-AD-0201 or Study ATH-1017-AD-0202.
The group in the trial
- TreatmentTreatment being tested
Daily subcutaneous (SC) injection of ATH-1017 - 40mg Dosage
Treatment: ATH-1017
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Open-Label Extension of Studies ATH-1017-AD-0201 and ATH-1017-AD-0202 in Subjects With Mild to Moderate Alzheimer's Disease
- Publications
- Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2024
- Record updated
- 1 April 2025